



- Abatacept – Orencia
- Agalsidase beta – Fabrazyme
- Alglucosidase alfa – Lumizyme
- Alpha1-proteinase inhibitor – Aralast, Glassia, Prolastin
- Anifrolumab – Saphnelo
- Avalglucosidase – Nexviazyme
- Belatacept – Nulogix
- Belimumab – Benlysta
- Benralizumab – Fasenna
- Blinatumomab – Blincyto
- Bezlotoxumab – Zinplava
- Cabotegravir – Apretude
- Cabotegravir/Rilpivirine – Cabenuva
- Canakinumab – Ilaris
- Crizanlizumab – Adakveo
- Dalbavancin – Dalvance
- Darbepoetin alfa – Aranesp
- Denosumab – Prolia & Xgeva
- Degarelix - Firmagon
- Dupilumab – Dupixent
- Edaravone – Radicava
- Eculizumab – Soliris
- Efgartigimod – Vyvgart
- Efgartigimod– Vyvgart Hytrulo
- Eptinezumab-jjmr – Vyepti
- Factor Products
- Filgrastim – Neupogen & biosimilars
- Fluorouracil – 5FU
- Golimumab – Simponi ARIA
- Goserelin - Zoladex
- Infliximab – Remicade & biosimilars
- Inclisiran – Leqvio
- Inebilizumab-cdon – Uplizna
- Immunoglobulin Intravenous – IVIg
- Immunoglobulin Subcutaneous – SCIg
- IV Antibiotics
- Leuprolide – Lupron
- Leuprolin - Eligard
- Lecanemab – Leqembi
- Natalizumab – Tysabri
- Omalizumab – Xolair
- Ocrelizumab – Ocrevus
- Ocrelizumab – Ocrevus Zunovo
- Octreotide – Sandostatin LAR
- Oritavancin – Orbactiv
- Pembrolizumab – Keytruda
- Pegfilgrastim – Neulasta & Biosimilars
- Pegloticase – Krystexxa
- Pertuzumab/Trastuzumab – Phesgo
- Remdesivir – Veklury
- Reslizumab – Cinqair
- Risankizumab – Skyrizi
- Rituximab – Rituxan & Biosimilars
- Romosozumab – Evenity
- Ravulizumab – Ultomiris
- Somatuline - Lanreotide
- Teplizumab-mzwv – Tziield
- Tezepelumab – Tezspire
- Teprotumumab – Tepezza
- Tocilizumab – Actemra
- Trabectedin – Yondelis
- Trastuzumab – Hylecta
- Ublituximab-xiiv – Briumvi
- Ustekinumab – Stelara
- Vedolizumab – Entyvio
- Vutrisiran – Amvuttra
- Zoledronic acid – Reclast & Zometa